Cargando…

Real-life Long-term Outcomes of Upfront Surgery in Patients with Resectable Stage I-IIIA Non-small Cell Lung Cancer

BACKGROUND: Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly evolving. When introducing novelties, real-life data on effectiveness of currently used treatment strategies are needed. The present study evaluated outcomes of stage I–IIIA NSCLC patients treated with upfront radical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bitenc, Marko, Cufer, Tanja, Kern, Izidor, Miklavcic, Martina, Petrovic, Sabrina, Groznik, Vida, Sadikov, Aleksander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400448/ https://www.ncbi.nlm.nih.gov/pubmed/35962955 http://dx.doi.org/10.2478/raon-2022-0030

Ejemplares similares

Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer
por: Koren, Ana, et al.
Publicado: (2021)

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
por: Stanic, Karmen, et al.
Publicado: (2014)

Erector spinae plane block versus intercostal nerve block for postoperative analgesia in lung cancer surgery
por: Gams, Polona, et al.
Publicado: (2023)

High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients
por: Koren, Ana, et al.
Publicado: (2017)

Managing elective surgery without preoperative testing during COVID-19 pandemic – Correspondence
por: Sabrina, Petrovic, et al.
Publicado: (2021)

Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting
por: Lekic, Mirko, et al.
Publicado: (2012)

The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
por: Sodja, Eva, et al.
Publicado: (2016)

Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival
por: Humar, Mojca, et al.
Publicado: (2017)

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung
por: Janzic, Urska, et al.
Publicado: (2017)

Automatic Spiral Analysis for Objective Assessment of Motor Symptoms in Parkinson’s Disease
por: Memedi, Mevludin, et al.
Publicado: (2015)

BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma
por: Koren, Ana, et al.
Publicado: (2016)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Idiopathic Pulmonary Fibrosis in Patients with Early-stage Non-small-cell Lung Cancer after Surgical Resection
por: Nezka, Hribernik, et al.
Publicado: (2019)

Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
por: Lowczak, Anna, et al.
Publicado: (2020)

Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non‐small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience
por: Savic, Milan, et al.
Publicado: (2017)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

Optimal approach for upfront resectable non-small-cell lung cancer
por: van Meerbeeck, Jan P.
Publicado: (2013)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer
por: Chen, Chih-Yu, et al.
Publicado: (2020)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
por: Pelicon, Veronika, et al.
Publicado: (2023)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

CXCL14 and NOS1 expression in specimens from patients with stage I–IIIA nonsmall cell lung cancer after curative resection
por: Ji, Xiaoqin, et al.
Publicado: (2018)

Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Clinical Outcomes of Upfront Primary Tumor Resection in Synchronous Unresectable Metastatic Colorectal Cancer
por: Shin, Ji Eun, et al.
Publicado: (2023)

The role of upfront primary tumor resection in asymptomatic patients with unresectable stage IV colorectal cancer: A systematic review and meta-analysis
por: Liang, Zongyu, et al.
Publicado: (2023)

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Zou, Yiping, et al.
Publicado: (2023)

Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2016)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer
por: Ding, Xiao, et al.
Publicado: (2012)

An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer
por: Berman, Abigail T, et al.
Publicado: (2013)

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
por: Hui, Zhouguang, et al.
Publicado: (2015)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h555hdgulgj3obd3bjdcsplefr